Peter Greenleaf Sells 797 Shares of Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock

Key Points

• Director Peter Greenleaf sold 797 shares on April 2 at an average price of $20.92 under a pre-arranged Rule 10b5-1 plan, trimming his stake by 3.13% to 24,681 shares valued at about $516,326.
• Shares surged 19.5% to $24.38 on above-average volume (28,715 vs. avg ~8,812); the stock has a market cap of $81.92M, a 52-week range of $9.00–$54.29 and a high beta of 3.93.
• Analyst and institutional interest is strong—five Buys and one Hold yield a "Moderate Buy" consensus with an average target of $55, and institutions own roughly 78% of the company with several funds recently increasing positions.

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS - Get Free Report) Director Peter Greenleaf sold 797 shares of the company's stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $20.92, for a total value of $16,673.24. Following the sale, the director directly owned 24,681 shares of the company's stock, valued at $516,326.52. The trade was a 3.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Stock Up 19.5%

Shares of NYSEAMERICAN:PTHS traded up $3.98 during trading on Monday, reaching $24.38. The stock had a trading volume of 28,715 shares, compared to its average volume of 8,812. The firm's fifty day moving average is $22.86. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.05 and a quick ratio of 1.15. Pelthos Therapeutics Inc. has a 52 week low of $9.00 and a 52 week high of $54.29. The stock has a market capitalization of $81.92 million, a price-to-earnings ratio of -1.17 and a beta of 3.93.

Analyst Ratings Changes

PTHS has been the subject of a number of research analyst reports. Piper Sandler assumed coverage on shares of Pelthos Therapeutics in a research report on Friday, February 27th. They set an "overweight" rating and a $48.00 target price for the company. Zacks Research upgraded Pelthos Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 24th. Oppenheimer boosted their price objective on Pelthos Therapeutics from $60.00 to $62.00 and gave the stock an "outperform" rating in a research report on Friday, March 20th. Roth Mkm decreased their target price on Pelthos Therapeutics from $57.00 to $55.00 and set a "buy" rating for the company in a research note on Thursday, February 26th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $60.00 target price on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $55.00.

Institutional Trading of Pelthos Therapeutics

A number of hedge funds have recently bought and sold shares of PTHS. Persistent Asset Partners Ltd increased its holdings in shares of Pelthos Therapeutics by 150.0% during the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company's stock worth $186,000 after purchasing an additional 3,604 shares during the period. Millennium Management LLC bought a new stake in shares of Pelthos Therapeutics in the fourth quarter valued at about $343,000. Geode Capital Management LLC grew its position in Pelthos Therapeutics by 31.9% during the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company's stock worth $422,000 after buying an additional 3,295 shares in the last quarter. Knott David M Jr grew its position in Pelthos Therapeutics by 215.5% during the fourth quarter. Knott David M Jr now owns 19,281 shares of the company's stock worth $598,000 after buying an additional 13,169 shares in the last quarter. Finally, Diadema Partners LP increased its stake in Pelthos Therapeutics by 138.1% during the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company's stock valued at $775,000 after acquiring an additional 14,502 shares during the period. 77.96% of the stock is owned by institutional investors.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.